Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Pediatr Infect Dis J. 2019 Jun;38(6):S2–S6. doi: 10.1097/INF.0000000000002317

Table 2. The use and purpose of galactomannan and β-D-glucan testing in serum in different patient populations from 13 children’s hospitals in the UK.

Biomarker Rational High risk neutropenic hemato-oncology patients Non-hematologic patients
GMN Screening 2/13 (15%) 1/13 (8%)
Diagnostic 10/13 (77%) 9/13 (69%)
BDG Screening 3/12 (25%) 1/12 (8%)
Diagnostic 7/12 (58%) 6/12 (50%)

GM: Galactomannan, BDG: β-D-Glucan